Cited by 163Nanoparticle-Based Drug DeliveryAntibiotics Pharmacokinetics and EfficacyRNA Interference and Gene Delivery

Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies

Open access
Schiffelers, R.·2001·Journal of Antimicrobial Chemotherapy

Abstract

Liposome-encapsulated amikacin has recently entered clinical trials. The rationale for liposome encapsulation of aminoglycosides is the possibility to increase the therapeutic index of this class of antibiotics by increasing aminoglycoside concentrations at the site of infection and/or by reducing the toxicity of these drugs. Three approaches can be distinguished: the use of liposomes as a depot formulation for local drug administration; targeting of (relatively) short circulating conventional liposomes to the cells of the mononuclear phagocyte system (MPS) for treating intracellular bacterial infections; and targeting of long-circulating liposomes to infectious foci localized outside the MPS. This review discusses the pre-clinical and clinical data in connection with recent developments in liposome technology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/48.3.333

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Despite early positive results in clinical trials for urinary tract infections and Mycobacterium infections, development of MiKasomes was discontinued in 2000.

    “Despite early positive results in clinical trials for urinary tract infections and Mycobacterium infections 15 , development of the formulation was discontinued in 2000.”

    From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [15]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 114 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. Gregoriadis, G. (1988). Fate of injected liposomes: obser- vations on entrapped solute retention vesicle clearance and tissue distribution in vivo. In Liposomes as Drug Carriers, Recent Trends and Progress, (Gregoriadis, G., Ed.), pp. 3-18. John Wiley and Sons, Chichester.
  2. Allen, T. M. (1988). Interactions of liposomes and other drug carriers with the mononuclear phagocyte system. In Liposomes as Drug Carriers, Recent Trends and Progress, (Gregoriadis, G., Ed.), pp. 37-50. John Wiley and Sons, Chichester.
  3. Ginsberg, R. S., Mitilenes, G. M. & Lenk, R. P. (1988). The impact of liposome encapsulation of gentamicin on the treatment of extracellular gram-negative bacterial infections. UCLA Symposium on Molecular Cell Biology New Series 89, 205-14.
  4. Storm, G. & Woodle, M. C. (1998). Long circulating liposome: from concept to clinical reality. In Long Circulating Liposomes: Old Drugs, New Therapeutics, (Woodle, M.C. & Storm, G., Eds), pp. 3-16. Springer Verlag, Berlin.

Cited by

Sorted by citations

Authors
Schiffelers, R.
Affiliations
Utrecht University (NL)
Corresponding author
Schiffelers, R.
Venue
Journal of Antimicrobial Chemotherapy
Published
2001-09-01
Volume
48
Issue
3
Pages
333-344
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2156636796
Cited by
163
References
114
Citations by year
2026: 5 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 10 · 2020: 4 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 7 · 2012: 7
FWCI
0.29
Type
journal article
Language
en
Open access
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
amikacin, liposomal drug delivery, therapeutic index, aminoglycoside toxicity, intracellular bacterial infection, long-circulating liposomes, local drug administration
MeSH terms
Aminoglycosides, Anti-Bacterial Agents, Clinical Trials as Topic, Drug Carriers, Humans, Infusions, Intravenous, Liposomes, Staphylococcus aureus, Drug Delivery Systems, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review